Population pharmacokinetics of the 5‐hydroxymethyl metabolite of tolterodine after administration of fesoterodine sustained release tablet in western and east Asian populations

Citations Over TimeTop 21% of 2014 papers

Abstract

This analysis was conducted to investigate factors that affect 5-hydroxymethyl tolterodine (5-HMT) pharmacokinetics after administration of fesoterodine sustained release tablets to Westerners and East Asians. Ten pharmacokinetic studies and three efficacy/safety studies in overactive bladder (OAB) patients were pooled for the population pharmacokinetic analysis. The plasma 5-HMT concentration data were described by a 1-compartment model with first order absorption and a lag time. Creatinine clearance (CLCR), hepatic impairment, CYP2D6 genotype, and concomitant medication with CYP3A inhibitor/inducer were identified as influential covariates. It was estimated that decreasing of CLCR from 80 to 15 mL/min resulted in a 39.5% reduction in 5-HMT apparent oral clearance (CL/F). Hepatic impairment, CYP2D6 poor metabolizer, and CYP3A inhibitor were estimated to reduce CL/F by about 60%, 40%, and 50%, respectively. CYP3A inducer resulted in about fourfold increase in CL/F. Although sex and Japanese ethnicity were selected as covariates on CL/F, each resulted in only about 10% decrease and increase of CL/F, respectively. Of the influential covariates of 5-HMT CL/F, CLCR, hepatic impairment, CYP2D6 genotype, and concomitant medication with CYP3A inhibitor/inducer were of significance, whereas sex and Japanese ethnicity covariates were considered not to have clinically significant impact on exposures of 5-HMT.

Related Papers

• → Tolterodine extended-release for overactive bladder(2009)13 cited
• Tolterodine in the treatment of idiopathic overactive bladder(2002)
• → MP-06.06: The efficacy of tolterodine and tamsulosin combination therapy in female OAB patients(2010)
• A Clinical Study of Domestic Tolterodine Tartrate Tablets for Urinary Bladder Hyperactivity(2001)
• Observation curative effects of treated 128 Cystospasm after TURP by Tolterodine combine Zolpidem(2011)